CN¥ 11.61
Key Takeaways
Risk factor
High price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
This pharmaceutical enterprise is dedicated to the comprehensive process of developing, manufacturing, and distributing medicinal products. Its diverse portfolio includes therapeutic solutions for children, respiratory ailments, cardiovascular and cerebrovascular disorders, digestive issues, trauma recovery, rehabilitation needs, and ophthalmic conditions. The company commenced operations in 1995 and maintains its primary base in Guiyang, China.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD
Data is available to registered users only